Show simple item record

dc.contributor.authorKurelac, I
dc.contributor.authorIommarinio, L
dc.contributor.authorVatrinet, R
dc.contributor.authorAmato, LB
dc.contributor.authorDe Luise, M
dc.contributor.authorLeone, G
dc.contributor.authorGirolimetti, G
dc.contributor.authorGanesh, NU
dc.contributor.authorBridgeman, VL
dc.contributor.authorOmbrato, L
dc.contributor.authorColumbaro, M
dc.contributor.authorRagazzi, M
dc.contributor.authorGibellini, L
dc.contributor.authorSollazzo, M
dc.contributor.authorFeichtinger, RG
dc.contributor.authorVidali, S
dc.contributor.authorBaldassarre, M
dc.contributor.authorForiel, S
dc.contributor.authorVidone, M
dc.contributor.authorCossarizza, A
dc.contributor.authorGrifoni, D
dc.contributor.authorKofler, B
dc.contributor.authorMalanchi, I
dc.contributor.authorPorcelli, AM
dc.contributor.authorGasparre, G
dc.date.accessioned2020-12-16T10:12:34Z
dc.date.available2019-01-30
dc.date.available2020-12-16T10:12:34Z
dc.date.issued2019-02-22
dc.identifier.issn2041-1723
dc.identifier.otherARTN 903
dc.identifier.otherARTN 903
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/69323
dc.description.abstractConverting carcinomas in benign oncocytomas has been suggested as a potential anti-cancerstrategy. One of the oncocytoma hallmarks is the lack of respiratory complex I (CI). Herewe use genetic ablation of this enzyme to induce indolence in two cancer types, andshow this is reversed by allowing the stabilization of Hypoxia Inducible Factor-1 alpha(HIF-1α). We further show that on the long run CI-deficient tumors re-adapt to their inabilityto respond to hypoxia, concordantly with the persistence of human oncocytomas. Wedemonstrate that CI-deficient tumors survive and carry out angiogenesis, despite theirinability to stabilize HIF-1α. Such adaptive response is mediated by tumor associated mac-rophages, whose blockage improves the effect of CI ablation. Additionally, the simultaneouspharmacological inhibition of CI function through metformin and macrophage infiltrationthrough PLX-3397 impairs tumor growth in vivo in a synergistic manner, setting the basisfor an efficient combinatorial adjuvant therapy in clinical trials.en_US
dc.relation.ispartofNATURE COMMUNICATIONS
dc.rightsCreative Commons Attribution 4.0 International License
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleInducing cancer indolence by targeting mitochondrial Complex I is potentiated by blocking macrophage-mediated adaptive responsesen_US
dc.typeArticleen_US
dc.rights.holder© The Author(s) 2019
dc.identifier.doi10.1038/s41467-019-08839-1
pubs.author-urlhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459403800008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6aen_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume10en_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution 4.0 International License
Except where otherwise noted, this item's license is described as Creative Commons Attribution 4.0 International License